Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Ben Taylor Sells 21,383 Shares

Key Points

• CFO Ben Taylor sold 21,383 shares on December 29 at an average price of $4.18 for about $89,381, trimming his stake by 2.73% to 761,550 shares (valued at roughly $3.18M).
• Recursion reported Q results showing ($0.36) EPS (beating estimates by $0.02) while revenue fell 80.1% year-over-year to $5.18M and the company has deeply negative margins and ROE.
• Shares traded near $4.11 (market cap ~$2.14B) with heavy institutional ownership (about 89%), and analysts have a consensus "Hold" rating with an average target price of $9.50.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CFO Ben Taylor sold 21,383 shares of the firm's stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $4.18, for a total value of $89,380.94. Following the completion of the sale, the chief financial officer directly owned 761,550 shares in the company, valued at $3,183,279. The trade was a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Recursion Pharmaceuticals Trading Down 0.5%

Shares of RXRX traded down $0.02 during trading hours on Tuesday, reaching $4.11. 17,828,137 shares of the company traded hands, compared to its average volume of 22,814,060. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The company's fifty day moving average price is $4.69 and its two-hundred day moving average price is $5.10. The company has a market capitalization of $2.14 billion, a price-to-earnings ratio of -2.28 and a beta of 0.94.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The company had revenue of $5.18 million for the quarter, compared to analysts' expectations of $19.36 million. During the same period in the prior year, the firm earned ($0.34) earnings per share. The firm's revenue for the quarter was down 80.1% on a year-over-year basis. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Recursion Pharmaceuticals by 183.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company's stock worth $33,901,000 after purchasing an additional 4,149,346 shares in the last quarter. Vanguard Group Inc. boosted its position in Recursion Pharmaceuticals by 10.3% during the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company's stock worth $194,127,000 after acquiring an additional 3,708,975 shares during the last quarter. Norges Bank acquired a new position in Recursion Pharmaceuticals in the 2nd quarter valued at $16,040,000. Bank Pictet & Cie Europe AG purchased a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at about $7,954,000. Finally, Geode Capital Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 20.7% during the 2nd quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company's stock valued at $39,353,000 after buying an additional 1,332,428 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

RXRX has been the topic of several recent research reports. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Needham & Company LLC reiterated a "buy" rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Morgan Stanley set a $11.00 target price on Recursion Pharmaceuticals in a report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $9.50.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.